BACKGROUND: Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are approved for venous thromboembolism (VTE) prophylaxis. Which agent is superior remains controversial.

Background: Unfractionated heparin (UFH) has been used clinically for 5 decades. Despite being a cornerstone of anticoagulation, UFH is limited by its unpredictable pharmacokinetic profile ...

Montalescot G, Zeymer U, Silvain J, et al.: Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international ...

There are two formulations of heparins, unfractionated heparin (UFH) and low molecular weight heparin (LMWH), used in clinical practice. Unfractionated heparin is used for both therapeutic ...

While similar in mechanism to unfractionated heparin, LMWH is cleared renally, has a much longer half-life and less commonly causes heparin-induced thrombocytopenia (HIT). Monitoring drug activity ...

Heparin, a widely used anticoagulant, prevents blood clots in veins and arteries. Both animal-derived unfractionated heparin and plasma-derived therapies are commonly used. “Major advancements ...

“Both unfractionated heparin, derived from animal sources like bovine and porcine, and plasma-derived therapies are popular,” it said. In addition, the market is driven by developments in ...

Unfractionated heparin, low-molecular-weight heparin (enoxaparin or fondaparinux) or bivalirudin may be used; unfractionated heparin should be given for 48 hours total and low molecular weight ...

Routine heparinization might reduce the likelihood of renal allograft thrombosis, but some investigators claim that this approach increases morbidity without exerting beneficial effects.